Cytoprotective Effect of Afobazole and Its Main Metabolite M-11
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605534837 | ||
| 003 | CHVBK | ||
| 005 | 20210128100844.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150501xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10517-015-2886-9 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10517-015-2886-9 | ||
| 245 | 0 | 0 | |a Cytoprotective Effect of Afobazole and Its Main Metabolite M-11 |h [Elektronische Daten] |c [I. Kadnikov, M. Voronin, S. Seredenin] |
| 520 | 3 | |a Cell damage depending on activity of quinone reductase 2 (MT3 receptor) was simulated in experiments on bone marrow cell suspension and assessed by menadione-induced DNA breaks measured by comet assay. We analyzed the protective effect of afobazole interacting with MT1, MT3, σ1 receptors, and monoamine oxidase A and its main metabolite M11 that specifi cally binds to MT3 receptors. Both compounds reduced the level of menadione-induced DNA damage (afobazole was effective in lower concentrations in comparison with M-11). Conclusion was made on the contribution of MT3 receptors to the protective effect of afobazole, but the observed concentration differences indicate possible contribution of other targets of anxiolytic drug to the protective mechanisms. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a afobazole |2 nationallicence | |
| 690 | 7 | |a MT3 receptor |2 nationallicence | |
| 690 | 7 | |a quinone reductase 2 |2 nationallicence | |
| 690 | 7 | |a cytoprotection |2 nationallicence | |
| 700 | 1 | |a Kadnikov |D I. |u V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | |
| 700 | 1 | |a Voronin |D M. |u V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | |
| 700 | 1 | |a Seredenin |D S. |u V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | |
| 773 | 0 | |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 159/1(2015-05-01), 44-47 |x 0007-4888 |q 159:1<44 |1 2015 |2 159 |o 10517 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10517-015-2886-9 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10517-015-2886-9 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kadnikov |D I. |u V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Voronin |D M. |u V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Seredenin |D S. |u V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 159/1(2015-05-01), 44-47 |x 0007-4888 |q 159:1<44 |1 2015 |2 159 |o 10517 | ||